Generate Biomedicines Inc.
GENB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GENB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GENB
Generate Biomedicines Inc. (GENB) is a clinical-stage biotechnology company leveraging its proprietary Generate Platform for drug discovery and development, with a lead candidate GB-0895 in clinical trials and no approved products or product revenue as of mid-2026.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.97B
Cash Runway
23.0 moLead Asset
gb-4362 (Phase 1)
Next Catalyst
Phase3_Topline · Dec 1, 2028Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials · 2 catalysts for Generate Biomedicines Inc..
Generate Biomedicines Inc. (GENB) is a clinical-stage biotechnology company leveraging its proprietary Generate Platform for drug discovery and development, with a lead candidate GB-0895 in clinical trials and no approved products or product revenue as of mid-2026.
- Generate Biomedicines has no products approved for sale and has not generated any revenue from product sales as of August 2026 [sec_mda · as of 2026-08-06].
- The company completed its initial public offering (IPO) on March 2, 2026, issuing 25,000,000 shares of common stock [sec_mda · as of 2026-08-06].
- As of June 30, 2026, the company reported cash and equivalents of $135.4M, total revenue of $6.3M, and a net loss of -$67.3M [sec].
- As of March 31, 2026, the company had an accumulated deficit of $737.7 million [sec_mda · as of 2026-05-07].
- The company expects its cash, cash equivalents, and marketable securities to fund operations into the first half of 2028, based on current operating plans [sec_mda · as of 2026-08-06].
What works
- The company has a proprietary Generate Platform that it uses for drug discovery and development, which may enable a pipeline of multiple preclinical programs in immunology and oncology [sec_mda · as of 2026-08-06].
- As of June 30, 2026, the company held $135.4M in cash and equivalents, providing a runway into the first half of 2028 to advance its programs [sec_mda · as of 2026-08-06].
What to weigh
- The company has no approved products and has never generated product revenue, relying entirely on its ability to develop and commercialize candidates [sec_mda · as of 2026-08-06].
- As of March 31, 2026, the company had an accumulated deficit of $737.7 million and expects operating losses to increase substantially as it expands clinical trials and research [sec_mda · as of 2026-05-07].
- The company faces significant uncertainty regarding the costs and timing of completing development for any product candidate, including GB-0895 [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
No approved products or product revenue
“We do not have any products approved for sale. To date, we have not generated any revenue from product sales.”
SEC MD&A · August 6, 2026
IPO completion date
“On March 2, 2026, we closed our initial public offering ("IPO"), pursuant to which we issued and sold 25,000,000 shares of common stock,”
SEC MD&A · August 6, 2026
Accumulated deficit as of March 31, 2026
“As of March 31, 2026, we had an accumulated deficit of $737.7 million.”
SEC MD&A · May 7, 2026
Cash runway estimate
“we believe, based on our current operating plan, our cash, cash equivalents and marketable securities will be sufficient to fund our current operating plan into the first half of 2028.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2028-12-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of G — Topline data from the Phase 3 trial of GB-0895 will be a key efficacy and safety readout for the lead candidate.
- 2029-01-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of G — A second Phase 3 topline readout for GB-0895 is scheduled, providing additional data on the candidate's profile.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no products approved for sale and has never generated product revenue, relying entirely on future development success [sec_mda · as of 2026-08-06].
- Significant accumulated deficit — As of March 31, 2026, accumulated deficit was $737.7 million, with net losses expected to increase substantially [sec_mda · as of 2026-05-07].
- Clinical development uncertainty — The company cannot reasonably estimate the costs or timing to complete development of any product candidate due to numerous risks [sec_mda · as of 2026-08-06].
- Need for additional capital — The company expects it will require additional funds to fully accomplish its planned uses of IPO proceeds [sec · filed 2026-02-04].
What to watch
- Phase 3 topline data for GB-0895 expected in December 2028 [catalyst].
- Cash burn rate and any updates to cash runway guidance in future SEC filings [sec_mda · as of 2026-08-06].
- Progress of preclinical programs in immunology and oncology advancing toward clinical trials [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Generate Biomedicines Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Generate Biomedicines Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
23.0 months
D/E 0.23 · 0% dilution
Lead: Phase 1
2 candidates
2 upcoming, next in ~824d
12 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
55
Total value held
$1.05B
| Holder | Shares | Value |
|---|---|---|
| flagship pioneering, llc | 62,673,117 | $783.4M |
| fmr llc | 4,217,524 | $52.7M |
| braidwell lp | 3,592,999 | $44.9M |
| arch venture management, llc | 1,944,426 | $24.3M |
| harbourvest partners llc | 1,722,210 | $21.5M |
| baker bros. advisors lp | 1,423,602 | $17.8M |
| harvard management co inc | 1,111,100 | $13.9M |
| nvidia corp | 833,325 | $10.4M |
| siren, l.l.c. | 736,104 | $9.2M |
| davern capital partners, lp | 591,800 | $7.4M |
Showing top 10 of 55 institutional holders of Generate Biomedicines Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 2.8%
- Days to cover
- 5.7
- Shares short
- 2,078,055
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GENB short interestFrequently asked questions
What is the AI investment thesis for Generate Biomedicines Inc.?
Generate Biomedicines Inc. (GENB) is a clinical-stage biotechnology company leveraging its proprietary Generate Platform for drug discovery and development, with a lead candidate GB-0895 in clinical trials and no approved products or product revenue as of mid-2026.
What is Generate Biomedicines Inc.'s lead drug candidate?
Generate Biomedicines Inc.'s most advanced tracked candidate is gb-4362 (Phase 1) for Advanced Urothelial Cancer.
What is Generate Biomedicines Inc.'s next catalyst?
Generate Biomedicines Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of G" — expected December 1, 2028.
Who is the CEO of Generate Biomedicines Inc.?
Mr. Michael T. Nally M.B.A. is the chief executive officer of Generate Biomedicines Inc. (GENB).
Where is Generate Biomedicines Inc. headquartered?
Generate Biomedicines Inc. (GENB) is headquartered in Somerville, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.